Search

Your search keyword '"Dumortier, Hélène"' showing total 170 results
Start Over Author "Dumortier, Hélène"
170 results on '"Dumortier, Hélène"'

1. Integrating Echocardiography Parameters With Explainable Artificial Intelligence for Data-Driven Clustering of Primary Mitral Regurgitation Phenotypes

Author

Bernard, Jérémy, Yanamala, Naveena, Shah, Rohan, Seetharam, Karthik, Altes, Alexandre, Dupuis, Marlène, Toubal, Oumhani, Mahjoub, Haïfa, Dumortier, Hélène, Tartar, Jean, Salaun, Erwan, O’Connor, Kim, Bernier, Mathieu, Beaudoin, Jonathan, Côté, Nancy, Vincentelli, André, LeVen, Florent, Maréchaux, Sylvestre, Pibarot, Philippe, and Sengupta, Partho P.

Published
2023
Full Text
View/download PDF

6. Tenascin‐C immobilizes infiltrating T lymphocytes through CXCL12 promoting breast cancer progression

Author

Murdamoothoo, Devadarssen, Sun, Zhen, Yilmaz, Alev, Riegel, Gilles, Abou‐Faycal, Chérine, Deligne, Claire, Velazquez‐Quesada, Ines, Erne, William, Nascimento, Marine, Mörgelin, Matthias, Cremel, Gérard, Paul, Nicodème, Carapito, Raphael, Veber, Romain, Dumortier, Hélène, Yuan, Jingping, Midwood, Kim S, Loustau, Thomas, and Orend, Gertraud

Published
2021
Full Text
View/download PDF

8. Data from Tenascin-C Orchestrates an Immune-Suppressive Tumor Microenvironment in Oral Squamous Cell Carcinoma

Author

Spenlé, Caroline, primary, Loustau, Thomas, primary, Murdamoothoo, Devadarssen, primary, Erne, William, primary, Beghelli-de la Forest Divonne, Stephanie, primary, Veber, Romain, primary, Petti, Luciana, primary, Bourdely, Pierre, primary, Mörgelin, Matthias, primary, Brauchle, Eva-Maria, primary, Cremel, Gérard, primary, Randrianarisoa, Vony, primary, Camara, Abdouramane, primary, Rekima, Samah, primary, Schaub, Sebastian, primary, Nouhen, Kelly, primary, Imhof, Thomas, primary, Hansen, Uwe, primary, Paul, Nicodème, primary, Carapito, Raphael, primary, Pythoud, Nicolas, primary, Hirschler, Aurélie, primary, Carapito, Christine, primary, Dumortier, Hélène, primary, Mueller, Christopher G., primary, Koch, Manuel, primary, Schenke-Layland, Katja, primary, Kon, Shigeyuki, primary, Sudaka, Anne, primary, Anjuère, Fabienne, primary, Van Obberghen-Schilling, Ellen, primary, and Orend, Gertraud, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Data from Tenascin-C Orchestrates an Immune-Suppressive Tumor Microenvironment in Oral Squamous Cell Carcinoma

Author

Spenlé, Caroline, primary, Loustau, Thomas, primary, Murdamoothoo, Devadarssen, primary, Erne, William, primary, Beghelli-de la Forest Divonne, Stephanie, primary, Veber, Romain, primary, Petti, Luciana, primary, Bourdely, Pierre, primary, Mörgelin, Matthias, primary, Brauchle, Eva-Maria, primary, Cremel, Gérard, primary, Randrianarisoa, Vony, primary, Camara, Abdouramane, primary, Rekima, Samah, primary, Schaub, Sebastian, primary, Nouhen, Kelly, primary, Imhof, Thomas, primary, Hansen, Uwe, primary, Paul, Nicodème, primary, Carapito, Raphael, primary, Pythoud, Nicolas, primary, Hirschler, Aurélie, primary, Carapito, Christine, primary, Dumortier, Hélène, primary, Mueller, Christopher G., primary, Koch, Manuel, primary, Schenke-Layland, Katja, primary, Kon, Shigeyuki, primary, Sudaka, Anne, primary, Anjuère, Fabienne, primary, Van Obberghen-Schilling, Ellen, primary, and Orend, Gertraud, primary

Published
2023
Full Text
View/download PDF

10. Identification of new candidate drugs for primary Sjögren's syndrome using a drug repurposing transcriptomic approach.

Author

Felten, Renaud, Ye, Tao, Schleiss, Cedric, Schwikowski, Benno, Sibilia, Jean, Monneaux, Fanny, Dumortier, Hélène, Jonsson, Roland, Lessard, Christopher, Ng, Fai, Takeuchi, Tsutomu, Mariette, Xavier, and Gottenberg, Jacques-Eric

Subjects
PHOSPHOTRANSFERASES, INTERFERONS, GENE expression profiling, INFORMATION resources, RESEARCH funding, SJOGREN'S syndrome, HISTONE deacetylase, LONGITUDINAL method
Abstract

Objectives To date, no immunomodulatory drug has demonstrated its efficacy in primary SS (pSS). We sought to analyse potential commonalities between pSS transcriptomic signatures and signatures of various drugs or specific knock-in or knock-down genes. Methods Gene expression from peripheral blood samples of patients with pSS was compared with that of healthy controls in two cohorts and three public databases. In each of the five datasets, we analysed the 150 most up- and downregulated genes between pSS patients and controls with regard to the differentially expressed genes resulting from the biological action on nine cell lines of 2837 drugs, 2160 knock-in and 3799 knock-down genes in the Connectivity Map database. Results We analysed 1008 peripheral blood transcriptomes from five independent studies (868 patients with pSS and 140 healthy controls). Eleven drugs could represent potential candidate drugs, with histone deacetylases and PI3K inhibitors among the most significantly associated. Twelve knock-in genes were associated with a pSS-like profile and 23 knock-down genes were associated with a pSS-revert profile. Most of those genes (28/35, 80%) were interferon-regulated. Conclusion This first drug repositioning transcriptomic approach in SS confirms the interest of targeting interferons and identifies histone deacetylases and PI3K inhibitors as potential therapeutic targets. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. Impact of dietary vitamin D on immunoregulation and disease pathology in lupus-prone NZB/W F1 mice

Author

Kraemer, Antoine N., primary, Schäfer, Anna-Lena, additional, Sprenger, Dalina T. L., additional, Sehnert, Bettina, additional, Williams, Johanna P., additional, Luo, Aileen, additional, Riechert, Laura, additional, Al-Kayyal, Qusai, additional, Dumortier, Hélène, additional, Fauny, Jean-Daniel, additional, Winter, Zoltan, additional, Heim, Kathrin, additional, Hofmann, Maike, additional, Herrmann, Martin, additional, Heine, Guido, additional, Voll, Reinhard E., additional, and Chevalier, Nina, additional

Published
2022
Full Text
View/download PDF

13. Significance of Left Ventricular Ejection Time in Primary Mitral Regurgitation

Author

Altes, Alexandre, primary, Bernard, Jérémy, additional, Dumortier, Hélène, additional, Dupuis, Marlène, additional, Toubal, Oumhani, additional, Mahjoub, Haïfa, additional, Tartar, Jean, additional, Côté, Nancy, additional, Clavel, Marie-Annick, additional, O'Connor, Kim, additional, Bernier, Mathieu, additional, Beaudoin, Jonathan, additional, Vincentelli, André, additional, Pibarot, Philippe, additional, and Maréchaux, Sylvestre, additional

Published
2022
Full Text
View/download PDF

14. Comparison of Mitral Regurgitant Volume Assessment between Proximal Flow Convergence and Volumetric Methods in Patients with Significant Primary Mitral Regurgitation: An Echocardiographic and Cardiac Magnetic Resonance Imaging Study

Author

Altes, Alexandre, primary, Levy, Franck, additional, Iacuzio, Laura, additional, Dumortier, Hélène, additional, Toledano, Manuel, additional, Tartar, Jean, additional, Tribouilloy, Christophe, additional, and Maréchaux, Sylvestre, additional

Published
2022
Full Text
View/download PDF

16. Variability of Primary Sjögren's Syndrome Is Driven by Interferon α and Interferon α Blood Levels Are Associated With the Class II HLA–DQ Locus

Author

Trutschel, Diana, Bost, Pierre, Mariette, Xavier, Bondet, Vincent, Llibre, Alba, Posseme, Celine, Charbit, Bruno, Thorball, Christian W., Jonsson, Roland, Lessard, Christopher J., Felten, Renaud, Ng, Wan Fai, Chatenoud, Lucienne, Dumortier, Hélène, Sibilia, Jean, Fellay, Jacques, Brokstad, Karl A., Appel, Silke, Tarn, Jessica R., Quintana‐Murci, Lluis, Mingueneau, Michael, Meyer, Nicolas, Duffy, Darragh, Schwikowski, Benno, Gottenberg, Jacques Eric, Dernis, Emmanuelle, Devauchelle‐Pensec, Valerie, Dieude, Philippe, Dubost, Jean‐Jacques, Fauchais, Anne‐Laure, Goeb, Vincent, Hachulla, Eric, Hatron, Pierre Yves, Larroche, Claire, Le Guern, Véronique, Morel, Jacques, Perdriger, Aleth, Salliot, Carinne, Rist, Stephanie, Saraux, Alain, Vittecoq, Olivier, Nocturne, Gaétane, Ravaud, Philippe, Seror, Raphaèle, Abel, Laurent, Alcover, Andres, Aschard, Hugues, Astrom, Kalla, Bousso, Philippe, Bruhns, Pierre, Cumano, Ana, Demangel, Caroline, Deriano, Ludovic, Di Santo, James, Dromer, Françoise, Eberl, Gérard, Enninga, Jost, Gelpi, Odile, GompertsBoneca, Ivo, Hasan, Milena, Hercberg, Serge, Lantz, Olivier, Leclerc, Claude, Mouquet, Hugo, Pellegrini, Sandra, Pol, Stanislas, Rausell, Antonio, Rogge, Lars, Sakuntabhai, Anavaj, Schwartz, Olivier, Shorte, Spencer, Soumelis, Vassili, Tangy, Frédéric, Tartour, Eric, Toubert, Antoine, Touvier, Mathilde, Ungeheuer, Marie‐Noëlle, Albert, Matthew L., Biomédecine computationelle des systèmes / Computational systems biomedicine, Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Universität Zürich [Zürich] = University of Zurich (UZH), Eidgenössische Technische Hochschule - Swiss Federal Institute of Technology [Zürich] (ETH Zürich), Service de Rhumatologie [CHU Bicêtre], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Projet NECESSITY (PN), Hôpitaux Universitaires Paris Sud [AP-HP] (HUPS)-Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Immunologie Translationnelle - Translational Immunology lab, Cytometrie et Biomarqueurs – Cytometry and Biomarkers (UTechS CB), Ecole Polytechnique Fédérale de Lausanne (EPFL), Université de Lausanne = University of Lausanne (UNIL), Lausanne University Hospital, University of Bergen (UiB), Oklahoma Medical Research Foundation (OMRF), University of Oklahoma Health Sciences Center (OUHSC), Université de Strasbourg (UNISTRA), Institut de biologie moléculaire et cellulaire (IBMC), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Newcastle University [Newcastle], Newcastle Upon Tyne Hospitals NHS Foundation Trust, Institut Necker Enfants-Malades (INEM - UM 111 (UMR 8253 / U1151)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Immunologie, Immunopathologie et Chimie Thérapeutique (I2CT), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Génétique Evolutive Humaine - Human Evolutionary Genetics, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Biogen Inc. [Cambridge, MA, USA], Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Supported by the Innovative Medicines Initiative 2 Joint Undertaking (JU) (grant 806975). The JU receives support from the European Union’s Horizon 2020 research and innovation program and the European Unionand the European Federation of Pharmaceutical Industries and Associations. This work was also supported by the National Institutes of Health (National Institute of Arthritis and Musculoskeletal Skin Disease grant R01-AR-065953). The Assessment of Systemic Signs and Evolution in Sjögren’s Syndrome(ASSESS) national multicenter prospective cohort was formed in 2006 with aFrench Ministry of Health grant (Programme Hospitalier de Recherche Clinique 2005 P060228). The ASSESS cohort is promoted by the French Society of Rheumatology and receives research grants from the French Society of Rheumatology. Dr. Gottenberg’s work was supported by Bristol Myers Squibbfor transcriptomic analysis of the ASSESS and Norwegian cohorts and by Geneviève Garnier (Association Française du Syndrome de Gougerot-Sjögrenet des syndromes secs). Drs. Trutschel’s and Schwikowski’s work was supported by Geneviève Garnier (Association Française du Syndrome de Gougerot-Sjögren et des syndromes secs)., Milieu Intérieur Consortium, ASSESS study investigators, and NECESSITY Consortium: Emmanuelle Dernis, Valerie Devauchelle-Pensec, Philippe Dieude, Jean-Jacques Dubost, Anne-Laure Fauchais, Vincent Goeb, Eric Hachulla, Pierre Yves Hatron, Claire Larroche, Véronique Le Guern, Jacques Morel, Aleth Perdriger, Carinne Salliot, Stephanie Rist, Alain Saraux, Jean Sibilia, Olivier Vittecoq, Gaétane Nocturne, Philippe Ravaud, Raphaèle Seror, Laurent Abel, Andres Alcover, Hugues Aschard, Kalla Astrom, Philippe Bousso, Pierre Bruhns, Ana Cumano, Caroline Demangel, Ludovic Deriano, James Di Santo, Françoise Dromer, Gérard Eberl, Jost Enninga, Jacques Fellay, Odile Gelpi, Ivo GompertsBoneca, Milena Hasan, Serge Hercberg, Olivier Lantz, Claude Leclerc, Hugo Mouquet, Sandra Pellegrini, Stanislas Pol, Antonio Rausell, Lars Rogge, Anavaj Sakuntabhai, Olivier Schwartz, Benno Schwikowski, Spencer Shorte, Vassili Soumelis, Frédéric Tangy, Eric Tartour, Antoine Toubert, Mathilde Touvier, Marie-Noëlle Ungeheuer, Matthew L Albert, Darragh Duffy, Lluis Quintana-Murci., European Project: 806975,NECESSITY, Clauss, Isabelle, and NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients - NECESSITY - 0000-00-00 - 0000-00-00 - 806975 - VALID

Subjects
Proteomics, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Sjogren's Syndrome, Rheumatology, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, HLA-DQ Antigens, Immunology, Humans, Interferon-alpha, Immunology and Allergy, Prospective Studies
Abstract

Objective: Primary Sjögren's syndrome (SS) is the second most frequent systemic autoimmune disease, affecting 0.1% of the general population. To characterize the molecular and clinical variabilities among patients with primary SS, we integrated transcriptomic, proteomic, cellular, and genetic data with clinical phenotypes in a cohort of 351 patients with primary SS. Methods: We analyzed blood transcriptomes and genotypes of 351 patients with primary SS who were participants in a multicenter prospective clinical cohort. We replicated the transcriptome analysis in 3 independent cohorts (n = 462 patients). We determined circulating interferon-α (IFNα) and IFNγ protein concentrations using digital single molecular arrays (Simoa). Results: Transcriptome analysis of the prospective cohort showed a strong IFN gene signature in more than half of the patients; this finding was replicated in the 3 independent cohorts. Because gene expression analysis did not discriminate between type I IFN and type II IFN, we used Simoa to demonstrate that the IFN transcriptomic signature was driven by circulating IFNα and not by IFNγ protein levels. IFNα protein levels, detectable in 75% of patients, were significantly associated with clinical and immunologic features of primary SS disease activity at enrollment and with increased frequency of systemic complications over the 5-year follow-up. Genetic analysis revealed a significant association between IFNα protein levels, a major histocompatibility (MHC) class II haplotype, and anti-SSA antibody. Additional cellular analysis revealed that an MHC class II HLA–DQ locus acts through up-regulation of HLA class II molecules on conventional dendritic cells. Conclusion: We identified the predominance of IFNα as a driver of primary SS variability, with IFNα demonstrating an association with HLA gene polymorphisms., Arthritis & Rheumatology, 74 (12), ISSN:2326-5191, ISSN:2326-5205

Published
2022
Full Text
View/download PDF

17. Significance of left ventricular ejection time in primary mitral regurgitation

Author

Altes, Alexandre, O'Connor, Kim, Bernard, Jérémy, Dumortier, Hélène, Mahjoub, Haïfa, Toubal, Oumhani, Côté, Nancy, Beaudoin, Jonathan, Tartar, Jean, Dupuis, Marlène, Bernier, Mathieu, Pibarot, Philippe, Clavel, Marie-Annick, Vincentelli, André, Maréchaux, Sylvestre, Altes, Alexandre, O'Connor, Kim, Bernard, Jérémy, Dumortier, Hélène, Mahjoub, Haïfa, Toubal, Oumhani, Côté, Nancy, Beaudoin, Jonathan, Tartar, Jean, Dupuis, Marlène, Bernier, Mathieu, Pibarot, Philippe, Clavel, Marie-Annick, Vincentelli, André, and Maréchaux, Sylvestre

Abstract

The optimal timing for mitral valve (MV) surgery in asymptomatic patients with primary mitral regurgitation (MR) remains controversial. We aimed at evaluating the relation between left ventricular ejection time (LVET) and outcome in patients with moderate or severe chronic primary MR because of prolapse. Clinical, Doppler echocardiographic, and outcome data prospectively collected from 302 patients (median age 61 [54 to 74] years, 34% women) with moderate or severe primary MR were analyzed. Patients were retrospectively stratified by quartiles of LVET. The primary end point of the study was the composite of need for MV surgery or all-cause mortality. During a median follow-up time of 66 (25th to 75th percentile, 33 to 95) months, 178 patients reached the primary end point. Patients in the lowest quartile of LVET (<260 ms) were at high risk for adverse events compared with those in the other quartiles of LVET (global p = 0.005), whereas the rate of events was similar for the other quartiles (p = NS for all). After adjustment for clinical predictors of outcome, including age, gender, history of atrial fibrillation, MR severity, and current recommended triggers for MV surgery in asymptomatic primary MR, LVET <260 ms was associated with an increased risk of events (adjusted hazard ratio 1.49, 95% confidence interval 1.03 to 2.16, p = 0.033). In conclusion, we observed that shorter LVET is associated with increased risk of adverse events in patients with moderate or severe primary MR because of prolapse. Further studies are required to investigate whether shorter LVET has a direct effect on outcomes or is solely a risk marker in primary MR.

Published
2022

22. OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response

Author

Jacquemin, Clément, Schmitt, Nathalie, Contin-Bordes, Cécile, Liu, Yang, Narayanan, Priya, Seneschal, Julien, Maurouard, Typhanie, Dougall, David, Davizon, Emily Spence, Dumortier, Hélène, Douchet, Isabelle, Raffray, Loïc, Richez, Christophe, Lazaro, Estibaliz, Duffau, Pierre, Truchetet, Marie-Elise, Khoryati, Liliane, Mercié, Patrick, Couzi, Lionel, Merville, Pierre, Schaeverbeke, Thierry, Viallard, Jean-François, Pellegrin, Jean-Luc, Moreau, Jean-François, Muller, Sylviane, Zurawski, Sandy, Coffman, Robert L., Pascual, Virginia, Ueno, Hideki, and Blanco, Patrick

Published
2015
Full Text
View/download PDF

24. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis

Author

Scherlinger, Marc, primary, Guillotin, Vivien, additional, Douchet, Isabelle, additional, Vacher, Pierre, additional, Boizard-Moracchini, Andréa, additional, Guegan, Jean-Philippe, additional, Garreau, Anne, additional, Merillon, Nathalie, additional, Vermorel, Agathe, additional, Ribeiro, Emmanuel, additional, Machelart, Irène, additional, Lazaro, Estibaliz, additional, Couzi, Lionel, additional, Duffau, Pierre, additional, Barnetche, Thomas, additional, Pellegrin, Jean-Luc, additional, Viallard, Jean-François, additional, Saleh, Maya, additional, Schaeverbeke, Thierry, additional, Legembre, Patrick, additional, Truchetet, Marie-Elise, additional, Dumortier, Hélène, additional, Contin-Bordes, Cécile, additional, Sisirak, Vanja, additional, Richez, Christophe, additional, and Blanco, Patrick, additional

Published
2021
Full Text
View/download PDF

29. Tenascin-C Orchestrates an Immune-Suppressive Tumor Microenvironment in Oral Squamous Cell Carcinoma

Author

Spenlé, Caroline, primary, Loustau, Thomas, additional, Murdamoothoo, Devadarssen, additional, Erne, William, additional, Beghelli-de la Forest Divonne, Stephanie, additional, Veber, Romain, additional, Petti, Luciana, additional, Bourdely, Pierre, additional, Mörgelin, Matthias, additional, Brauchle, Eva-Maria, additional, Cremel, Gérard, additional, Randrianarisoa, Vony, additional, Camara, Abdouramane, additional, Rekima, Samah, additional, Schaub, Sebastian, additional, Nouhen, Kelly, additional, Imhof, Thomas, additional, Hansen, Uwe, additional, Paul, Nicodème, additional, Carapito, Raphael, additional, Pythoud, Nicolas, additional, Hirschler, Aurélie, additional, Carapito, Christine, additional, Dumortier, Hélène, additional, Mueller, Christopher G., additional, Koch, Manuel, additional, Schenke-Layland, Katja, additional, Kon, Shigeyuki, additional, Sudaka, Anne, additional, Anjuère, Fabienne, additional, Van Obberghen-Schilling, Ellen, additional, and Orend, Gertraud, additional

Published
2020
Full Text
View/download PDF

32. LIST OF CONTRIBUTORS

Author

Abu-Shakra, Mahmoud, primary, Achiron, Anat, additional, Alderuccio, Frank, additional, Amital, Howard, additional, Ansari, Aftab A., additional, Aoki, Christopher A., additional, Arepally, Gowthami, additional, Aries, Peer M., additional, Atzeni, Fabiola, additional, Bachmann, Michael, additional, Bendtzen, Klaus, additional, Berden, Jo H., additional, Bertolaccini, Maria Laura, additional, Betterle, Corrado, additional, Bianchi, Francesco B., additional, Binder, Steven R., additional, Bizzaro, Nicola, additional, Borghi, Maria O., additional, Bowlus, Christopher L., additional, Božič, Borut, additional, Bradwell, Arthur R., additional, Bruschi, Maurizio, additional, Burek, C. Lynne, additional, Candiano, Giovanni, additional, Carp, H.J.A., additional, Caturegli, Patrizio, additional, Cerinic, Marco Matucci, additional, Cervera, Ricard, additional, Chan, Edward K.L., additional, Chang, Yih-Hsin, additional, Chen, Shu, additional, Cicardi, Marco, additional, Cines, Douglas B., additional, Cohen, Irun R., additional, Conrad, Karsten, additional, Csernok, Elena, additional, Čučnik, Saša, additional, De Angelis, Valentina, additional, Dier, Ken J., additional, Dotan, Nir, additional, Dueymes, Maryvonne, additional, Dumortier, Hélène, additional, Lahawi, Mohammed El, additional, Faulk, W. Page, additional, Feist, Eugen, additional, Forster, Olaf, additional, Fritzler, Marvin J., additional, Frostegård, Johan, additional, Fujinami, Robert S., additional, Furmaniak, Jadwiga, additional, Galli, Monica, additional, Gerosa, Maria, additional, Gershwin, M. Eric, additional, Ghiggeri, Gian Marco, additional, Gilles, Jean Guy, additional, Grando, Sergei A., additional, Graus, Francesc, additional, Gross, Wolfgang L., additional, Guiducci, Serena, additional, Guilpain, Philippe, additional, Hamann, Dörte, additional, Hamilton, Robert G., additional, Harel, Michal, additional, Haung, Ming-Lih, additional, Heidenreich, Fedor, additional, Hellmark, Thomas, additional, Herkel, Johannes I., additional, Hershko, Alon Y., additional, Hiepe, Falk, additional, Hilfiker-Kleiner, Denise, additional, Hughes, Richard G., additional, Hultman, Per, additional, Invernizzi, Pietro, additional, Izui, Shozo, additional, Jirawuthiworavong, Guy V., additional, Kallenberg, Cees G.M., additional, Karim, Abid R., additional, Kaveri, Srinivas V., additional, Khamashta, Munther A., additional, Kind, Michaela, additional, Knoflach, Michael, additional, Kodermaz, Graziano, additional, Krueger, Christian, additional, Kveder, Tanja, additional, Landolfo, Santo, additional, Lang, Bethan, additional, Leung, Patrick S.C., additional, Levy-Clarke, Grace A., additional, Lindert, Ralf-Björn, additional, Lochman, Ivo, additional, Lochmanová, Alexandra, additional, Lopez, Luis R., additional, Loy, Anthony Chin, additional, Manns, Michael P., additional, Matsumoto, Isao, additional, Matsuura, Eiji, additional, McCarty, Gale A., additional, McHugh, Neil John, additional, McIntyre, John A., additional, Meroni, Pier Luigi, additional, Miron, Shmuel, additional, Mondini, Michele, additional, Mouthon, Luc, additional, Muller, Sylviane, additional, Muratori, Paolo, additional, Musante, Luca, additional, Muthugounder, Sakunthala, additional, Naguwa, Stanley, additional, Nakamura, Tomomi, additional, Naparstek, Yaakov, additional, Narain, Sonali, additional, Nussenblat, Robert B., additional, Nydegger, Urs E., additional, Oertelt, Sabine, additional, Pengo, Vittorio, additional, Peterson, Lisa K., additional, Pietropaolo, Massimo, additional, Podda, Mauro, additional, Pollard, K. Michael, additional, Poncz, Mortimer, additional, Prestigiacomo, Tony, additional, Radice, Antonella, additional, Randone, Silvia Bellando, additional, Raschi, Elena, additional, Ravindranath, Mepur H., additional, Ravindranath, Rajeswari M.H., additional, Reeves, Westley H., additional, Reichlin, Morris, additional, Renaudineau, Yves, additional, Riboldi, Piersandro, additional, Ronda, Nicoletta, additional, Rose, Noel R., additional, Rosenberg, Nurit, additional, Routsias, John G., additional, Rozman, B., additional, Ruffatti, Amelia, additional, Sabadini, Ettore, additional, Saint-Remy, Jean-Marie, additional, Salomon, Ophira, additional, Santucci, Laura, additional, Sarzi-Puttini, Piercarlo, additional, Satoh, Minoru, additional, Schlosser, Michael, additional, Scofield, R. Hal, additional, Segelmark, Mårten, additional, Selmi, Carlo, additional, Seo, Suk, additional, Shenkman, Boris, additional, Shiau, Ming-Yuh, additional, Shoenfeld, Yehuda, additional, Sinico, Renato Alberto, additional, Sliwa, Karen, additional, Smeenk, Ruud J.T., additional, Smolen, Josef S., additional, Sperling, Mark A., additional, Stadler, Beda M., additional, Steiner, Günter, additional, Stöcker, Winfried, additional, Strassburg, Christian P., additional, Sumida, Takayuki, additional, Sundstrom, J. Bruce, additional, Svenson, Morten, additional, Targoff, Ira N., additional, Tedesco, Francesco, additional, Toh, Ban-Hock, additional, Tonutti, Elio, additional, Torens, Isabel, additional, Torok, Natalie, additional, Tozzoli, Renato, additional, Tsokos, George C., additional, Tzioufas, Athanasios G., additional, Ulmansky, Rina, additional, van Bavel, Casandra C., additional, van der Vlag, Johan, additional, Villalta, Danilo, additional, Vincent, Angela, additional, Wagenknecht, Dawn R., additional, Wakamatsu, Ei, additional, Wener, Mark H., additional, Wesierska-Gadek, Józefa, additional, Wick, Georg, additional, Wiik, Allan, additional, Willison, Hugh J., additional, Witte, Torsten, additional, Wurster, Ulrich, additional, Youinou, Pierre, additional, Zanchetta, Renato, additional, Zandman-Goddard, Gisele, additional, Zhuang, Haoyang, additional, Zingale, Lorenza C., additional, and Zuliani, Luigi, additional

Published
2007
Full Text
View/download PDF

34. Multifunctional Carbon Nanodots: Enhanced Near‐Infrared Photosensitizing, Photothermal Activity, and Body Clearance.

Author

Ji, Ding-Kun, Dali, Hayet, Guo, Shi, Malaganahally, Sowmya, Vollaire, Julien, Josserand, Véronique, Dumortier, Hélène, Ménard-Moyon, Cécilia, and Bianco, Alberto

Subjects
NEAR infrared radiation, PHOTOTHERMAL effect, FOLIC acid, NANOMEDICINE, BLOOD circulation
Abstract

The emergence of quasispherical carbon nanodots (CNDs) has broadened the family of carbon‐based materials and their applications in many fields. However, the rational design of near‐infrared (NIR) CNDs and their specific applications in theranostic biomedicine are still challenging. Herein, the design and characterization of multifunctional CNDs (MCNDs) as NIR laser‐triggered nanoagents are reported. These MCNDs are constructed by covalent functionalization of CNDs with folic acid and a hydrophobic photosensitizer, chlorin e6 (Ce6), based on a double amidation approach. The resulting MCNDs show high colloidal stability in different physiological environments. They are endowed with NIR fluorescence emission, an enhanced NIR photosensitizing, and a high photothermal activity. The in vitro test indicates that MCNDs own an efficient targeting capacity to penetrate into cancer cells, leading to cell killing at a low dose under NIR laser irradiation. Finally, MCNDs display a long blood circulation time in mice and effective body clearance through a dual hepatobiliary and renal elimination pathway. These features are encouraging for their use as NIR laser‐triggered nanoagents for personalized medicine. This work not only paves a new way for the multifunctionalization of CNDs, simply by integrating other functional components, but also broadens their versatile applications in targeted cancer theranostic nanomedicine. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

36. Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells

Author

Sawaf, Matthieu, Fauny, Jean-Daniel, Felten, Renaud, Sagez, Flora, Gottenberg, Jacques-Eric, Dumortier, Hélène, Monneaux, Fanny, Clauss, Isabelle, Immunologie, Immunopathologie et Chimie Thérapeutique (I2CT), Institut de biologie moléculaire et cellulaire (IBMC), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], and This work was supported by the French CNRS, a grant from the Fondation Arthritis-Courtin (to FM), the French Ministère de l’Enseignement et de la Recherche, and a fellowship from ELIA Medical (to MS).

Subjects
Adult, CD4-Positive T-Lymphocytes, Male, Adolescent, Immunology, Programmed Cell Death 1 Receptor, Lupus, Autoimmunity, Lymphocyte Activation, Autoimmune Diseases, Young Adult, immune system diseases, Humans, Lupus Erythematosus, Systemic, CTLA-4 Antigen, Receptors, Immunologic, skin and connective tissue diseases, Aged, Cell Proliferation, Aged, 80 and over, Middle Aged, Lipid Metabolism, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, [SDV.IMM.IA] Life Sciences [q-bio]/Immunology/Adaptive immunology, Female, France, Research Article, Signal Transduction
Abstract

International audience; Coinhibitory receptors play an important role in the prevention of autoimmune diseases, such as systemic lupus erythematosus (SLE), by limiting T cell activation. B and T lymphocyte attenuator (BTLA) is an inhibitory receptor, similar to cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD1), that negatively regulates the immune response. The role of BTLA in the pathogenesis of autoimmune diseases in humans and, more specifically, in SLE is largely unknown. We investigated BTLA expression on various T cell subsets, and we did not observe significant variations of BTLA expression between lupus patients and healthy controls. However, the enhancement of BTLA expression after activation was significantly lower in SLE patients compared with that in healthy controls. Furthermore, we found an impaired capacity of BTLA to inhibit T cell activation in SLE due to a poor BTLA recruitment to the immunological synapse following T cell stimulation. Finally, we demonstrated that defective BTLA function can be corrected by restoring intracellular trafficking and by normalizing the lipid metabolism in lupus CD4+ T cells. Collectively, our results evidence that the BTLA signaling pathway is altered in SLE T cells and highlight the potential of targeting this pathway for the development of new therapeutic strategies in lupus.

Published
2018
Full Text
View/download PDF

38. Follicular Helper T Cells in Systemic Lupus Erythematosus: Why Should They Be Considered as Interesting Therapeutic Targets?

Author

Sawaf, Matthieu, Dumortier, Hélène, and Monneaux, Fanny

Subjects
Adult, 0301 basic medicine, lcsh:Immunologic diseases. Allergy, Cellular differentiation, Plasma Cells, Immunology, Review Article, Pathogenesis, 03 medical and health sciences, medicine, Humans, Lupus Erythematosus, Systemic, Immunology and Allergy, Molecular Targeted Therapy, skin and connective tissue diseases, B cell, Autoantibodies, Autoimmune disease, B-Lymphocytes, Systemic lupus erythematosus, Lupus erythematosus, business.industry, Autoantibody, Germinal center, Cell Differentiation, T-Lymphocytes, Helper-Inducer, General Medicine, Germinal Center, medicine.disease, 030104 developmental biology, medicine.anatomical_structure, business, lcsh:RC581-607
Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by B cell hyperactivity leading to the production of autoantibodies, some of which having a deleterious effect. Reducing autoantibody production thus represents a way of controlling lupus pathogenesis, and a better understanding of the molecular and cellular factors involved in the differentiation of B cells into plasma cells could allow identifying new therapeutic targets. Follicular helper T cells (TFH) represent a distinct subset of CD4+T cells specialized in providing help to B cells. They are required for the formation of germinal centers and the generation of long-lived serological memory and, as such, are suspected to play a central role in SLE. Recent advances in the field ofTFHbiology have allowed the identification of important molecular factors involved inTFHdifferentiation, regulation, and function. Interestingly, some of theseTFH-related molecules have been described to be dysregulated in lupus patients. In the present review, we give an overview of the aberrant expression and/or function of such key players in lupus, and we highlight their potential as therapeutic targets.

Published
2016

39. Identification of autoreactive B cells with labeled nucleosomes

Author

Gies, Vincent, primary, Wagner, Alain, additional, Seifert, Cécile, additional, Guffroy, Aurélien, additional, Fauny, Jean-D., additional, Knapp, Anne-M., additional, Pasquali, Jean-L., additional, Martin, Thierry, additional, Dumortier, Hélène, additional, Korganow, Anne-S., additional, and Soulas-Sprauel, Pauline, additional

Published
2017
Full Text
View/download PDF

41. Carbon nanotube-coupled cell adhesion peptides are non-immunogenic: a promising step toward new biomedical devices

Author

Gaillard, Claire, Duval, Monique, Dumortier, Hélène, Bianco, Alberto, Immunologie et chimie thérapeutiques (ICT), and Cancéropôle du Grand Est-Centre National de la Recherche Scientifique (CNRS)

Subjects
Nanotubes, Carbon, Enzyme-Linked Immunosorbent Assay, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, [CHIM.THER]Chemical Sciences/Medicinal Chemistry, Peptides
Abstract

International audience; Carbon nanotubes functionalized with cell adhesion peptides can be considered as novel, promising candidates for the development of advanced drug delivery systems or for designing new generation of self-assembling nerve 'bridges'. An important step toward the integration of these types of conjugates in living bodies is the assessment of their impact on the immune system. In this direction, an integrin-derived peptide has been covalently conjugated to carbon nanotubes. Following intraperitoneal administration, peptide-carbon nanotubes do not trigger an anti-peptide antibody production. Demonstration of the immune neutrality of peptide-carbon nanotubes reinforces their potential use as substrates for neuronal regeneration in vivo. Copyright © 2010 European Peptide Society and John Wiley & Sons, Ltd.

Published
2011
Full Text
View/download PDF

42. CD209+ Macrophages Resist Dengue Virus

Author

Kwan, Wing-Hong, Navarro-Sanchez, Erika, Dumortier, Hélène, Decossas, Marion, Vachon, Hortense, dos Santos, Flavia Barreto, Fridman, Hervé W, Rey, Félix A., Harris, Eva, Desprès, Philippe, Mueller, Christopher G, Pansiot, Sylvie, Immunologie et chimie thérapeutiques (ICT), Cancéropôle du Grand Est-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Interactions Moléculaires Flavivirus-Hôtes, Institut Pasteur [Paris] (IP), Virologie Structurale, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Division of Infectious Diseases, University of California (UC), and This work was supported by INSERM, CNRS, the Fondation de la Recherche Me´ dicale, the Agence Nationale de Recherche Microbiologie Immunologie Maladies Emergentes (contract ARBO-CELLGUARD), the Pediatric Dengue Vaccine Initiative (PDVI), and the European Commission (INCO-DEV, contract DENFRAME No. 51711). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Subjects
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, viruses, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Abstract

International audience; BACKGROUND: An important question in dengue pathogenesis is the identity of immune cells involved in the control of dengue virus infection at the site of the mosquito bite. There is evidence that infection of immature myeloid dendritic cells plays a crucial role in dengue pathogenesis and that the interaction of the viral envelope E glycoprotein with CD209/DC-SIGN is a key element for their productive infection. Dermal macrophages express CD209, yet little is known about their role in dengue virus infection. METHODS AND FINDINGS: Here, we showed that dermal macrophages bound recombinant envelope E glycoprotein fused to green fluorescent protein. Because dermal macrophages stain for IL-10 in situ, we generated dermal-type macrophages from monocytes in the presence of IL-10 to study their infection by dengue virus. The macrophages were able to internalize the virus, but progeny virus production was undetectable in the infected cells. In addition, no IFN-alpha was produced in response to the virus. The inability of dengue virus to grow in the macrophages was attributable to accumulation of internalized virus particles into poorly-acidified phagosomes. CONCLUSIONS: Aborting infection by viral sequestration in early phagosomes would present a novel means to curb infection of enveloped virus and may constitute a prime defense system to prevent dengue virus spread shortly after the bite of the infected mosquito.

Published
2008
Full Text
View/download PDF

46. Cutting edge: small molecule CD40 ligand mimetics promote control of parasitemia and enhance T cells producing IFN-gamma during experimental Trypanosoma cruzi infection.

Author

Habib, Mohammed, Rivas, Magali Noval, Chamekh, Mostafa, Wieckowski, Sébastien, Sun, Weimin, Bianco, Alberto, Trouche, Nathalie, Chaloin, Olivier, Dumortier, Hélène, Goldman, Michel, Guichard, Gilles, Fournel, Sylvie, Vray, Bernard, Habib, Mohammed, Rivas, Magali Noval, Chamekh, Mostafa, Wieckowski, Sébastien, Sun, Weimin, Bianco, Alberto, Trouche, Nathalie, Chaloin, Olivier, Dumortier, Hélène, Goldman, Michel, Guichard, Gilles, Fournel, Sylvie, and Vray, Bernard

Abstract

Host resistance to Trypanosoma cruzi infection depends on a type 1 response characterized by a strong production of IL-12 and IFN-gamma. Amplifying this response through CD40 triggering results in control of parasitemia. Two newly synthesized molecules (<3 kDa) mimicking trimeric CD40L (mini CD40Ls(-1) and (-2)) bind to CD40, activate murine dendritic cells, and elicit IL-12 production. Wild-type but not CD40 knockout mice exhibited a sharp decrease of parasitemia and mortality when inoculated with T. cruzi mixed with miniCD40Ls. Moreover, the immunosuppression induced by T. cruzi infection was impaired in mice treated with miniCD40Ls, as shown by proliferation of splenic lymphocytes, percentage of CD8(+) T cells, and IFN-gamma production. Mice surviving T. cruzi infection in the presence of miniCD40L(-1) were immunized against a challenge infection. Our results indicate that CD40L mimetics are effective in vivo and promote the control of T. cruzi infection by overcoming the immunosuppression usually induced by the parasites., Journal Article, Research Support, Non-U.S. Gov't, info:eu-repo/semantics/published

Published
2007

47. C3-symmetric Peptide Scaffolds are Functional Mimetics of Trimeric CD40l

Author

Fournel, Sylvie, Schneider, Pascal, Vray, Bernard, Toes, René EM, Offringa, Rienk, Melief, Cornelis Jm C.J.M., Hoebeke, Johan, Guichard, Gilles, Wieckowski, Sébastien, Sun, Weimin, Trouche, Nathalie, Dumortier, Hélène, Bianco, Alberto, Chaloin, Olivier, Habib, Mohammed, Peter, Jean Christophe, Fournel, Sylvie, Schneider, Pascal, Vray, Bernard, Toes, René EM, Offringa, Rienk, Melief, Cornelis Jm C.J.M., Hoebeke, Johan, Guichard, Gilles, Wieckowski, Sébastien, Sun, Weimin, Trouche, Nathalie, Dumortier, Hélène, Bianco, Alberto, Chaloin, Olivier, Habib, Mohammed, and Peter, Jean Christophe

Abstract

Interaction between CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, and its ligand CD40L, a 39-kDa glycoprotein, is essential for the development of humoral and cellular immune responses1, 2. Selective blockade or activation of this pathway provides the ground for the development of new treatments against immunologically based diseases3, 4 and malignancies5, 6. Like other members of the TNF superfamily, CD40L monomers self-assemble around a threefold symmetry axis to form noncovalent homotrimers that can each bind three receptor molecules7, 8. Here, we report on the structure-based design of small synthetic molecules with C3 symmetry that can mimic CD40L homotrimers. These molecules interact with CD40, compete with the binding of CD40L to CD40, and reproduce, to a certain extent, the functional properties of the much larger homotrimeric soluble CD40L. Architectures based on rigid C3-symmetric cores may thus represent a general approach to mimicking homotrimers of the TNF superfamily. © 2005 Nature Publishing Group. All rights reserved., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results